In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Earlier in October, Pfizer Inc (NYSE: PFE) reported its third quarter revenue grew 14% on an operational basis due to ...

Moderna’s (NASDAQ:MRNA) Q3 results confirmed on Thursday that the U.S. vaccine market for respiratory syncytial virus (RSV), ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

Pfizer and partner BioNTech have launched a countersuit against Moderna in a patent dispute centring on their mRNA-based vaccines for COVID-19. Moderna fired the first volley back in August ...

Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.

Moderna said it is suing Pfizer and its German partner BioNTech for patent infringement linked to the development of the first Covid-19 vaccines. The US biotech company is alleging that mRNA ...

Moderna and Pfizer have both said that updated versions of their COVID-19 vaccines work against the highly mutated BA.2.86 variant, also known as Pirola, which is being closely watched by health ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

With flu season underway and new, developing COVID-19 strains, health professionals continue to stress the importance of receiving an updated vaccine. On Oct. 23, the Centers for Disease Control ...